IDiyas

For the Inventor, By the Inventor

Brookline, MA, United States of America

Brian Stephen Gerstenberger

USPTO Granted Patents = 14 

 

 

Average Co-Inventor Count = 9.6

ph-index = 2

Forward Citations = 16(Granted Patents)


Location History:

  • Brookline, MA (US) (2017 - 2022)
  • Cambridge, MA (US) (2021 - 2023)

Company Filing History:

goldMedal14 out of 4,455 
 
Pfizer Corporation
 patents

Years Active: 2017-2025

Loading Chart...
Loading Chart...
Loading Chart...
14 patents (USPTO):
1. 12312344 - N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors (2025-05-27),
2. 12129256 - Pyrazolo[1,5-a]pyrazin-4-yl derivatives (2024-10-29),
3. 11708360 - N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors (2023-07-25),
4. 11661419 - Benzimidazole derivative compounds and uses thereof (2023-05-30),
5. 11655252 - Aminopyrimidinyl derivatives (2023-05-23),
6. 11472809 - Pyrazolo[1,5-a]pyrazin-4-yl derivatives (2022-10-18),
7. 11254668 - Pyrazolo[1,5-A]pyrazin-4-yl and related derivatives (2022-02-22),
8. 11197867 - Aminopyrimidinyl compounds (2021-12-14),
9. 10980815 - Aminopyrimidinyl compounds (2021-04-20),
10. 10975065 - N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors (2021-04-13),
11. 10822341 - Pyrazolo[1,5-a]pyrazin-4-yl derivatives (2020-11-03),
12. 10463675 - Aminopyrimidinyl compounds (2019-11-05),
13. 10144738 - Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives (2018-12-04),
14. 9663526 - Aminopyrimidinyl compounds (2017-05-30),

Title: The Innovative Work of Brian Stephen Gerstenberger in Pharmaceutical Research

Introduction

Brian Stephen Gerstenberger, a prolific inventor based in Brookline, MA (US), has made significant contributions to the field of pharmaceuticals with a total of 12 patents to his name. His groundbreaking research focuses on developing compounds that inhibit CC chemokine receptor 6 (CCR6) and benzimidazole derivatives for various medicinal applications.

Latest Patents

Gerstenberger's latest patents include:

1. N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides as CCR6 inhibitors: These compounds are designed to inhibit CCR6, offering potential treatments for a range of diseases and disorders related to this receptor.

2. Benzimidazole derivative compounds: These compounds function as ITK inhibitors, showing promise in the treatment of conditions like atopic dermatitis.

Career Highlights

Working at Pfizer Corporation, Gerstenberger has been instrumental in developing novel pharmaceutical compounds with diverse applications. His work showcases a deep understanding of medicinal chemistry and drug design, aiming to address unmet medical needs effectively.

Collaborations

Gerstenberger has collaborated with esteemed colleagues at Pfizer Corporation, including Andrew Fensome and Li Huang Xing. These collaborations have enriched his research insights and led to the successful development of innovative pharmaceutical compounds.

Conclusion

Brian Stephen Gerstenberger's inventive spirit and dedication to advancing pharmaceutical research have positioned him as a key figure in the industry. His patents reflect a commitment to improving healthcare outcomes through cutting-edge drug discovery. The future holds great potential for Gerstenberger's continued contributions to the field of pharmaceutical innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…